4.15
Sab Biotherapeutics Inc Azioni (SABS) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
| Data di fine periodo | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
| Revenues |
-
|
- | - | - | 0.1147 |
|
|
24.38%
15.77
|
12.68 | 9.7321 | 10.77 | 10.12 |
| Operating Income/Loss |
24.38%
-15.77
|
-12.68 | -9.7321 | -10.77 | -10.01 |
| Nonoperating Income/Loss |
101.88%
-1.0905
|
58.12 | -0.3822 | 5.5753 | -1.3859 |
| Income/Loss From Continuing Operations Before Tax |
137.10%
-16.86
|
45.45 | -10.11 | -5.1968 | 24.03 |
| Income/Loss From Continuing Operations After Tax |
137.10%
-16.86
|
45.45 | -10.11 | -5.1968 | -11.39 |
|
|
137.10%
-16.86
|
45.45 | -10.11 | -5.1968 | -11.39 |
| Preferred Stock Dividends And Other Adjustments |
134.94%
-14.02
|
40.11 | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
10.31%
9.5613
|
10.66 | 9.2945 | 9.2916 | 0.00982 |
| Diluted Average Shares |
60.14%
31.04
|
77.86 | 9.2945 | 9.2916 | 0.00982 |
| Basic Earnings Per Share |
202.00%
-0.51
|
0.50 | -1.09 | -0.56 | -1.23 |
| Diluted Earnings Per Share |
119.05%
-0.46
|
-0.21 | -1.09 | -0.56 | -1.23 |
| Undistributed Earnings/Loss Allocated To Participating Securities, Basic |
134.94%
-14.02
|
40.11 | - | - | - |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
134.94%
-28.03
|
80.22 | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):